PATIENT SQUARE CAPITAL LP
Q3 2026 Form 13-F
MENLO PARK, CALIFORNIA
CIK 0001819257
· CRD 312203
· SEC-registered investment adviser
$626.7M Reported Value Total
PATIENT SQUARE CAPITAL, LP reports 30 total accounts under management (AUM). There are 30 discretionary accounts valued at $17,512,552,081, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
32 funds
· $17.2B gross asset value
Private Equity Fund: $17.2B
Source: Form ADV filed 2026-05-26
Reported value
$626.7M
Quarter over quarter
-0.8%
Holdings
23
Top-10 concentration
80.6%
Key People
Form ADV owners & control persons
James Cameron Momtazee
MANAGING MEMBER
Carolyn Joy Drayer-Greenwalt
CHIEF COMPLIANCE OFFICER AND MANAGING DIRECTOR
Adam Mark Fliss
FOUNDING PARTNER; HEAD OF STRATEGY, CAPITAL, LEGAL, AND GOVERNMENT AFFAIRS
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 10, 2026 |
| Form | 13F-HR |
| Reported value | $626.7M |
| Positions | 23 |
| Change in reported value | -2.9% |
| New positions | 6 |
| Exited positions | 6 |
| Position turnover | 41.4% |
| Top-10 concentration | 80.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 10, 2026
|
23 | $626.7M |
|
Q2 2026 13F
Filed Aug 12, 2026
|
23 | $645.5M |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $563.6M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
28 | $467.1M |
|
Q3 2025 13F
Filed Nov 10, 2025
|
24 | $373.9M |
|
Q2 2025 13F
Filed Aug 11, 2025
|
19 | $277.4M |
|
Q1 2025 13F
Filed May 14, 2025
|
19 | $241.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
20 | $267.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
11 | $269.4M |
|
Q2 2024 13F
Filed Aug 13, 2024
|
2 | $215.4M |
|
Q1 2024 13F
Filed May 14, 2024
|
2 | $234.8M |
|
Q4 2023 13F
Filed Feb 13, 2024
|
2 | $182.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
2 | $182.0M |
|
Q2 2023 13F
Filed Aug 11, 2023
|
2 | $205.4M |
|
Q1 2023 13F
Filed May 10, 2023
|
2 | $124.4M |
|
Q4 2022 13F
Filed Feb 13, 2023
|
2 | $236.5M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ROIV ROIVANT SCIENCES LTD | $282.0M | 45.0% |
| 2 | RVMD REVOLUTION MEDICINES INC | $40.2M | 6.42% |
| 3 | UTHR UNITED THERAPEUTICS CORP DEL | $34.0M | 5.42% |
| 4 | ARGX ARGENX SE | $26.8M | 4.28% |
| 5 | PHVS PHARVARIS N V | $25.7M | 4.09% |
| 6 | ABVX ABIVAX SA | $24.1M | 3.84% |
| 7 | BLTE BELITE BIO INC | $22.4M | 3.57% |
| 8 | MIRM MIRUM PHARMACEUTICALS INC | $20.0M | 3.19% |
| 9 | ZLAB ZAI LAB LTD | $15.6M | 2.49% |
| 10 | DFTX DEFINIUM THERAPEUTICS INC | $14.7M | 2.34% |
| 11 | CMPS COMPASS PATHWAYS PLC | $13.1M | 2.1% |
| 12 | DBVT DBV TECHNOLOGIES S A | $13.0M | 2.07% |
| 13 | ONC BEONE MEDICINES LTD | $12.3M | 1.96% |
| 14 | COGT COGENT BIOSCIENCES INC | $11.6M | 1.85% |
| 15 | RCUS ARCUS BIOSCIENCES INC | $10.6M | 1.69% |
| 16 | BNTX BIONTECH SE | $10.4M | 1.65% |
| 17 | ELVN ENLIVEN THERAPEUTICS INC | $9.7M | 1.55% |
| 18 | PCVX VAXCYTE INC | $9.4M | 1.51% |
| 19 | KYMR KYMERA THERAPEUTICS INC | $9.4M | 1.5% |
| 20 | ALLO ALLOGENE THERAPEUTICS INC | $7.3M | 1.16% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.